The Infectious Diseases Society of America (IDSA) continues to view with concern the lean
pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by …

The ongoing explosion of antibiotic-resistant infections continues to plague global and US
health care. Meanwhile, an equally alarming decline has occurred in the research and …

Background Alternative therapies for Staphylococcus aureus bacteremia and endocarditis
are needed. Methods We randomly assigned 124 patients with S. aureus bacteremia with or …

The frequency of methicillin-resistant Staphylococcus aureus (MRSA) infections continues to
grow in hospital-associated settings and, more recently, in community settings in the United …

Infections caused by antibiotic-resistant bacteria, especially the “ESKAPE” pathogens, continue
to increase in frequency and cause significant morbidity and mortality. New antimicrobial …

Background Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive
pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 …

Background. The safety of adding initial low-dose gentamicin to antistaphylococcal
penicillins or vancomycin for treatment of suspected Staphylococcus aureus native valve …

Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for …

Importance Infections due to Staphylococcus aureus are serious complications of cardiothoracic
surgery. A novel vaccine candidate (V710) containing the highly conserved S aureus …

The past few years have seen the advent of several new antifungal agents, including those
of a new class and a new generation of an existing class. Caspofungin, the first available …